Dementia and Alzheimer Disease

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Medicare recipients living with Alzheimer disease who have documented evidence of beta-amyloid plaque can now receive coverage for lecanemab through participating clinics and registries.

Neurology News Network for the week ending July 8, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 7, 2023.

The decision was based on findings from the phase 3 confirmatory Clarity AD study, in which treatment with the agent resulted in significant reductions in amyloid-ß in the brain.

Robert Glanzman, MD, the chief medical officer at the ImmunoBrain Checkpoint, talked about IBC-Ab002 as a promising anti-PD-L1 monoclonal antibody to improve cognition in patients with Alzheimer disease.

In this episode of MEDcast, expert geriatric psychiatrist and neurologist delve into the recent advances in the treatment of Alzheimer’s disease. We will discuss treatments that are on the cusp of FDA approval and others that are coming down the pipeline.

In this episode of MEDcast, expert geriatric psychiatrist and neurologist delve into the recent advances in the treatment of Alzheimer’s disease. We will discuss treatments that are on the cusp of FDA approval and others that are coming down the pipeline.

The fallout from the pandemic has shaped a growing public health concern and a call for a new clinical pathway to account for the intersection between culture, ethnicity, race, and aging.

Here's some of what is coming soon to NeurologyLive® this week.

Recent advances in artificial intelligence—particularly conversational AI tools such as ChatGPT—suggest promising potential in addressing the issues of loneliness and social isolation in these patient populations.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Through a quantitative electroencephalogram, investigators observed brainwave changes in several regions of the brain following treatment with CT1812.

Neurology News Network for the week ending July 1, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 30, 2023.

The professor of neurology at the University of California, Irvine, talked about social determinants of health in Alzheimer disease and the importance of having diverse populations in clinical trials. [WATCH TIME: 4 minutes]

The associate professor at Johns Hopkins School of Nursing provided insight on a presentation at SLEEP 2023, and whether neurofilament light should be more considered when assessing elderly patients with sleep disorders. [WATCH TIME: 5 minutes]

With the approval, Roche has 3 FDA-cleared tests that are reflective of the main Alzheimer disease pathologies and help clinicians more completely define the disease biologically.

The associate professor of environmental and occupational Health at the University of California, Irvine, talked about the impact of concentrated particulate matter or air pollution on cognitive function in animal models. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 23, 2023.

Expert geriatric psychiatrists explore a frequently encountered symptom in Alzheimer’s disease, agitation. We will discuss its impact on patient’s and care giver’s quality of life, the current standard of care and the first FDA approved agent for treatment of agitation symptoms in Alzheimer’s disease.

Expert geriatric psychiatrists explore a frequently encountered symptom in Alzheimer’s disease, agitation. We will discuss its impact on patient’s and care giver’s quality of life, the current standard of care and the first FDA approved agent for treatment of agitation symptoms in Alzheimer’s disease.